Ads
related to: zuranolone for postpartum depression treatment
Search results
Results from the WOW.Com Content Network
The FDA is about to decide whether to approve the first-ever pill for postpartum depression. The medication could also get approved for clinical depression.
The first-ever pill for postpartum depression, zuranolone, was approved last year. ... so only certain treatment centers are allowed to administer it and patients must stay in the hospital for 2 1 ...
Zuranolone, sold under the brand name Zurzuvae, is a medication used for the treatment of postpartum depression. [5] [6] It is taken by mouth.[5]The most common side effects include drowsiness, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection.
In August the Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication to treat postpartum depression.The approval is a big step for women with the condition, which ...
The day after the trial participants completed a 14-day treatment course of zuranolone, the researchers found that 57% reported a 50% or higher improvement in their depressive symptoms, compared ...
In 2023, the FDA approved zuranolone, sold under the brand name Zurzuvae for treatment of postpartum depression. Zuranolone is administered through a pill, which is more convenient than brexanolone, which is administered through an intravenous injection. [130]
Ads
related to: zuranolone for postpartum depression treatment